News from the healthcare data industry
June 09, 2022 01:03 ET | Source: F. Hoffmann-La Roche Ltd FoundationOne CDx can now be used to identify patients with ROS1 fusion-positive non-small cell lung cancer or patients with NTRK fusion-positive solid tumours for whom...
June 07, 2022 08:00 AM Eastern Daylight Time RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and contract services to the life sciences...
Paris, June 8, 2022. Sanofi announces the launch of its first Digital Accelerator to foster its ambition to become a leading digital healthcare company. The Accelerator will develop products and...
June 8, 2022 Michael Howley PA-C, MBA, PhD, Peter Malamis, MBA Survey taken by pharma and CRO executives evaluates how effectively various programs convert RWD into usable data. We have previously...
SAN FRANCISCO and FORT LAUDERDALE, Fla., June 07, 2022 (GLOBE NEWSWIRE) — The COVID-19 Research Database (the Database), a pro bono initiative led by numerous prominent companies whose mission is...
Singapore – 7 June 2022: GE Healthcare today announces a new collaboration with National Cancer Centre Singapore (NCCS), which focuses on how artificial intelligence (AI) driven research can be used to...
CHICAGO, June 7, 2022 /PRNewswire/ — EVERSANA™, a pioneer of next-generation commercial services to the global life sciences industry, today unveiled EVERSANA INTOUCH, marking the transformation of its full-service, global healthcare agency network serving the...
Global healthcare data management and analytics leader brings together experts to discuss current drivers in personalized medicine at second edition of Precision Medicine & Data Science Conference in Singapore ZURICH, June 6, 2022 /PRNewswire/ — BC Platforms (BCP),...
Initial Goal of Collaboration is to Develop FoundationOne®Liquid CDx as a Companion Diagnostic for Bavdegalutamide (ARV-110), Arvinas’ Investigational Androgen Receptor-Targeting PROTAC® Protein Degrader June 05, 2022 08:05 AM Eastern Daylight...
NEW YORK–(BUSINESS WIRE)– Pfizer Inc. (NYSE:PFE) today announced overall survival (OS) results from the Phase 3 PALOMA-2 trial, which evaluated IBRANCE® (palbociclib) in combination with letrozole compared to placebo plus...